An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Transplantation of an individual's own tissue from one site to another site.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7)
Methionine Sulfoximine is a toxic compound that functions as an inhibitor of methionine metabolism, being formed through the oxidation of methionine by the enzyme methionine sulfoxide reductase.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Inorganic or organic compounds that contain the basic structure RB(OH)2.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Pyrazines are heterocyclic organic compounds containing a six-membered ring with two nitrogen atoms at opposite positions, often responsible for the characteristic flavors and aromas found in various foods, beverages, and some biological systems, but they do not have a direct medical definition as they are not a drug, treatment, or a significant component of human physiology or pathology.
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
The farthest or outermost projections of the body, such as the HAND and FOOT.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
A mutant strain of Rattus norvegicus without a thymus and with depressed or absent T-cell function. This strain of rats may have a small amount of hair at times, but then lose it.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
An anti-inflammatory 9-fluoro-glucocorticoid.
An alkylating agent of value against both hematologic malignancies and solid tumors.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
A group of alkylating agents derived from mustard gas, with the sulfur replaced by nitrogen. They were formerly used as toxicants and vesicants, but now function as antineoplastic agents. These compounds are also powerful mutagens, teratogens, immunosuppressants, and carcinogens.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A 3:1 mixture of alfaxalone with alfadolone acetate that previously had been used as a general anesthetic. It is no longer actively marketed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1445)
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Nitroimidazoles are a class of antibacterial and antiprotozoal drugs, which, upon reduction, interact with bacterial or protozoal DNA leading to inhibition of nucleic acid synthesis and ultimately cell death, used primarily in the treatment of anaerobic infections and certain parasitic diseases.
Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA.
Drugs used for their actions on histaminergic systems. Included are drugs that act at histamine receptors, affect the life cycle of histamine, or affect the state of histaminergic cells.

L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. (1/1170)

PET with L-[1-11C]-tyrosine (TYR) was investigated in patients undergoing hyperthermic isolated limb perfusion (HILP) with recombinant tumor necrosis factor alpha (rTNF-alpha) and melphalan for locally advanced soft-tissue sarcoma and skin cancer of the lower limb. METHODS: Seventeen patients (5 women, 12 men; age range 24-75 y; mean age 52 y) were studied. TYR PET studies were performed before HILP and 2 and 8 wk afterwards. The protein synthesis rates (PSRs) in nanomoles per milliliter per minute were calculated. After final PET studies, tumors were resected and pathologically examined. Patients with pathologically complete responses (pCR) showed no viable tumors after treatment. Those with pathologically partial responses (pPR) showed various amounts of viable tumors in the resected tumor specimens. RESULTS: Six patients (35%) showed a pCR and 11 patients (65%) showed a pPR. All tumors were depicted as hot spots on PET studies before HILP. The PSR in the pCR group at 2 and 8 wk after perfusion had decreased significantly (P < 0.05) in comparison to the PSR before HILP. A significant difference was found in PSR between the pCR and pPR groups at 2 and at 8 wk (P < 0.05). Median PSR in nonviable tumor tissue was 0.62 and ranged from 0.22 to 0.91. With a threshold PSR of 0.91, sensitivity and specificity of TYR PET were 82% and 100%, respectively. The predictive value of a PSR > 0.91 for having viable tumor after HILP was 100%, whereas the predictive value of a PSR < or = 0.91 for having nonviable tumor tissue after HILP was 75%. The 2 patients in the pPR groups with a PSR < 0.91 showed microscopic islets of tumor cells surrounded by extensive necrosis on pathological examination. CONCLUSION: Based on the calculated PSR after HILP, TYR PET gave a good indication of the pathological outcome. Inflammatory tissue after treatment did not interfere with viable tumor on the images, suggesting that it may be worthwhile to pursue TYR PET in other therapy evaluation settings.  (+info)

In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. (2/1170)

Isolated perfusion of the extremities with high-dose tumour necrosis factor alpha (TNF-alpha) plus melphalan leads to dramatic tumour response in patients with irresectable soft tissue sarcoma or multiple melanoma in transit metastases. We developed in vivo isolated organ perfusion models to determine whether similar tumour responses in solid organ tumours can be obtained with this regimen. Here, we describe the technique of isolated kidney perfusion. We studied the feasibility of a perfusion with TNF-alpha and assessed its anti-tumour effects in tumour models differing in tumour vasculature. The maximal tolerated dose (MTD) proved to be only 1 microg TNF-alpha. Higher doses appeared to induce renal failure and a secondary cytokine release with fatal respiratory and septic shock-like symptoms. In vitro, the combination of TNF-alpha and melphalan did not result in a synergistic growth-inhibiting effect on CC 531 colon adenocarcinoma cells, whereas an additive effect was observed on osteosarcoma ROS-1 cells. In vivo isolated kidney perfusion, with TNF-alpha alone or in combination with melphalan, did not result in a significant anti-tumour response in either tumour model in a subrenal capsule assay. We conclude that, because of the susceptibility of the kidney to perfusion with TNF-alpha, the minimal threshold concentration of TNF-alpha to exert its anti-tumour effects was not reached. The applicability of TNF-alpha in isolated kidney perfusion for human tumours seems, therefore, questionable.  (+info)

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. (3/1170)

Integrin-mediated adhesion influences cell survival and may prevent programmed cell death. Little is known about how drug-sensitive tumor cell lines survive initial exposures to cytotoxic drugs and eventually select for drug-resistant populations. Factors that allow for cell survival following acute cytotoxic drug exposure may differ from drug resistance mechanisms selected for by chronic drug exposure. We show here that drug-sensitive 8226 human myeloma cells, demonstrated to express both VLA-4 (alpha4beta1) and VLA-5 (alpha5beta1) integrin fibronectin (FN) receptors, are relatively resistant to the apoptotic effects of doxorubicin and melphalan when pre-adhered to FN and compared with cells grown in suspension. This cell adhesion mediated drug resistance, or CAM-DR, was not due to reduced drug accumulation or upregulation of anti-apoptotic Bcl-2 family members. As determined by flow cytometry, myeloma cell lines selected for drug resistance, with either doxorubicin or melphalan, overexpress VLA-4. Functional assays revealed a significant increase in alpha4-mediated cell adhesion in both drug-resistant variants compared with the drug-sensitive parent line. When removed from selection pressure, drug-resistant cell lines reverted to a drug sensitive and alpha4-low phenotype. Whether VLA-4-mediated FN adhesion offers a survival advantage over VLA-5-mediated adhesion remains to be determined. In conclusion, we have demonstrated that FN-mediated adhesion confers a survival advantage for myeloma cells acutely exposed to cytotoxic drugs by inhibiting drug-induced apoptosis. This finding may explain how some cells survive initial drug exposure and eventually express classical mechanisms of drug resistance such as MDR1 overexpression.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (4/1170)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). (5/1170)

Tumour-selective acidification is of potential interest for enhanced therapeutic gain of pH sensitive drugs. In this study, we investigated the feasibility of a tumour-selective reduction of the extracellular and intracellular pH and their effect on the tumour response of selected anti-cancer drugs. In an in vitro L1210 leukaemic cell model, we confirmed enhanced cytotoxicity of chlorambucil at low extracellular pH conditions. In contrast, the alkylating drugs melphalan and cisplatin, and bioreductive agents mitomycin C and its derivative EO9, required low intracellular pH conditions for enhanced activation. Furthermore, a strong and pH-independent synergism was observed between the pH-equilibrating drug nigericin and melphalan, of which the mechanism is unclear. In radiation-induced fibrosarcoma (RIF-1) tumour-bearing mice, the extracellular pH was reduced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) or its analogue benzylguanidine (BG) plus glucose. To simultaneously reduce the intracellular pH, MIBG plus glucose were combined with the ionophore nigericin or the Na+/H+ exchanger inhibitor amiloride and the Na+-dependent HCO3-/Cl- exchanger inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS). Biochemical studies confirmed an effective reduction of the extracellular pH to approximately 6.2, and anti-tumour responses to the interventions indicated a simultaneous reduction of the intracellular pH below 6.6 for at least 3 h. Combined reduction of extra- and intracellular tumour pH with melphalan increased the tumour regrowth time to 200% of the pretreatment volume from 5.7 +/- 0.6 days for melphalan alone to 8.1 +/- 0.7 days with pH manipulation (P < 0.05). Mitomycin C related tumour growth delay was enhanced by the combined interventions from 3.8 +/- 0.5 to 5.2 +/- 0.5 days (P < 0.05), but only in tumours of relatively large sizes. The interventions were non-toxic alone or in combination with the anti-cancer drugs and did not affect melphalan biodistribution. In conclusion, we have developed non-toxic interventions for sustained and selective reduction of extra- and intracellular tumour pH which potentiated the tumour responses to selected anti-cancer drugs.  (+info)

Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. (6/1170)

Transplantation after high-dose chemotherapy prolongs survival in patients with multiple myeloma compared with standard therapy. It is unclear whether the optimal timing of transplantation is immediately after induction chemotherapy or whether stem cells may be cryopreserved for transplantation at subsequent progression or relapse. In this study, stem cells were collected within 6 months of diagnosis, followed by transplantation only at progression of myeloma. One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved. Eleven had transplants early in the disease after they demonstrated failure to respond to primary therapy. The remaining 107 were eligible for transplants when there was evidence of progressive disease. Of the 118 patients, 67 had transplants, nine died of progressive disease before transplantation, and 42 remain alive in plateau phase. The median survival of the group is 58.5 months; 67 are alive. Serum beta2-microglobulin, bone marrow labeling index (S phase), and hemoglobin level predicted overall survival (P < 0.006, P < 0.001, and P < 0.01, respectively). We conclude that early cryopreservation of blood stem cells followed by transplantation at progression is a feasible approach to therapy in patients with myeloma. The underlying biology of the disease has a greater impact on survival than the timing of transplantation. A prospective randomized trial is required to answer definitively the question of the optimal timing of blood cell transplantation.  (+info)

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. (7/1170)

A patient with a stage IV mantle cell lymphoma (according to the REAL classification) was treated with high-dose chemotherapy and autologous bone marrow transplantation. One year later while on alpha-interferon immunotherapy she suffered from progressive loss of short-term memory and reported difficulties in recognizing objects. Magnetic resonance imaging (MRI) showed a vast ring-enhancing lesion of the left postcentral parietal area. Serial stereotactic biopsies disclosed progressive multifocal leukoencephalopathy without JC-virus in the cerebrospinal fluid. Therapy with subcutaneous interleukin-2 (IL-2) every other day and intrathecal cytarabine once a week was started. After 4 weeks the patient refused further treatment. Nevertheless her condition improved over the next 8 months and MRI scans showed a marked improvement in the lesions.  (+info)

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. (8/1170)

The idiotype (Id) determinant on the multiple myeloma (MM) protein can be regarded as a tumor-specific marker. Immunotherapy directed at the MM Id may stem the progression of this disease. We report here on the first 12 MM patients treated at our institution with high-dose therapy and peripheral blood stem cell transplantation (PBSCT) followed by Id immunizations. MM patients received PBSCT to eradicate the majority of the disease. PBSCT produced a complete response in 2 patients, a partial response in 9 patients and stable disease in 1 patient. Three to 7 months after high-dose therapy, patients received a series of monthly immunizations that consisted of two intravenous infusions of Id-pulsed autologous dendritic cells (DC) followed by five subcutaneous boosts of Id/keyhole limpet hemocyanin (KLH) administered with adjuvant. Between 1 and 11 x 10(6) DC were obtained by leukapheresis in all patients even after PBSCT. The administration of Id-pulsed DC and Id/KLH vaccines were well tolerated with patients experiencing only minor and transient side effects. Two of 12 patients developed an Id-specific, cellular proliferative immune response and one of three patients studied developed a transient but Id-specific cytotoxic T-cell (CTL) response. Eleven of the 12 patients generated strong KLH-specific cellular proliferative immune responses showing the patients' immunocompetence at the time of vaccination. The two patients who developed a cellular Id-specific immune response remain in complete remission. Of the 12 treated patients, 9 are currently alive after autologous transplantation with a minimum follow-up of 16 months, 2 patients died because of recurrent MM and 1 patient succumbed to acute leukemia. These studies show that patients make strong anti-KLH responses despite recent high-dose therapy and that DC-based Id vaccination is feasible after PBSCT and can induce Id-specific T-cell responses. Further vaccine development is necessary to increase the proportion of patients that make Id-specific immune responses. The clinical benefits of Id vaccination in MM remain to be determined.  (+info)

Melphalan is an antineoplastic agent, specifically an alkylating agent. It is used in the treatment of multiple myeloma and other types of cancer. The medical definition of Melphalan is:

A nitrogen mustard derivative that is used as an alkylating agent in the treatment of cancer, particularly multiple myeloma and ovarian cancer. Melphalan works by forming covalent bonds with DNA, resulting in cross-linking of the double helix and inhibition of DNA replication and transcription. This ultimately leads to cell cycle arrest and apoptosis (programmed cell death) in rapidly dividing cells, such as cancer cells.

Melphalan is administered orally or intravenously, and its use is often accompanied by other anticancer therapies, such as radiation therapy or chemotherapy. Common side effects of Melphalan include nausea, vomiting, diarrhea, and bone marrow suppression, which can lead to anemia, neutropenia, and thrombocytopenia. Other potential side effects include hair loss, mucositis, and secondary malignancies.

It is important to note that Melphalan should be used under the close supervision of a healthcare professional, as it can cause serious adverse reactions if not administered correctly.

Regional perfusion chemotherapy for cancer is a medical treatment in which a specific area or region of the body is infused with high concentrations of cancer-killing (cytotoxic) drugs via a temporary isolation and perfusion of that region. This technique is typically used to treat isolated areas of cancer that are locally advanced, recurrent, or cannot be removed surgically.

The procedure involves isolating the regional blood circulation by cannulating the artery and vein that supply blood to the target area, often the limbs (such as in melanoma or sarcoma) or the liver (for liver tumors). The chemotherapeutic drugs are then introduced into the isolated arterial circulation, allowing for a high concentration of the drug to be delivered directly to the cancerous tissue while minimizing systemic exposure and toxicity.

After the infusion, the region is rinsed with a blood-substitute solution to remove any residual chemotherapeutic agents before reconnecting the circulation. This procedure can be repeated multiple times if necessary.

Regional perfusion chemotherapy has been shown to improve local control and potentially increase survival rates in certain types of cancer, while reducing systemic side effects compared to traditional intravenous chemotherapy. However, it is a complex and invasive procedure that requires specialized medical expertise and facilities.

Antineoplastic agents, alkylating, are a class of chemotherapeutic drugs that work by alkylating (adding alkyl groups) to DNA, which can lead to the death or dysfunction of cancer cells. These agents can form cross-links between strands of DNA, preventing DNA replication and transcription, ultimately leading to cell cycle arrest and apoptosis (programmed cell death). Examples of alkylating agents include cyclophosphamide, melphalan, and cisplatin. While these drugs are designed to target rapidly dividing cancer cells, they can also affect normal cells that divide quickly, such as those in the bone marrow and digestive tract, leading to side effects like anemia, neutropenia, thrombocytopenia, and nausea/vomiting.

Multiple myeloma is a type of cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help your body fight infection by producing antibodies. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Rather than producing useful antibodies, the cancer cells produce abnormal proteins that can cause complications such as kidney damage, bone pain and fractures.

Multiple myeloma is a type of cancer called a plasma cell neoplasm. Plasma cell neoplasms are diseases in which there is an overproduction of a single clone of plasma cells. In multiple myeloma, this results in the crowding out of normal plasma cells, red and white blood cells and platelets, leading to many of the complications associated with the disease.

The abnormal proteins produced by the cancer cells can also cause damage to organs and tissues in the body. These abnormal proteins can be detected in the blood or urine and are often used to monitor the progression of multiple myeloma.

Multiple myeloma is a relatively uncommon cancer, but it is the second most common blood cancer after non-Hodgkin lymphoma. It typically occurs in people over the age of 65, and men are more likely to develop multiple myeloma than women. While there is no cure for multiple myeloma, treatments such as chemotherapy, radiation therapy, and stem cell transplantation can help manage the disease and its symptoms, and improve quality of life.

Autologous transplantation is a medical procedure where cells, tissues, or organs are removed from a person, stored and then returned back to the same individual at a later time. This is different from allogeneic transplantation where the tissue or organ is obtained from another donor. The term "autologous" is derived from the Greek words "auto" meaning self and "logos" meaning study.

In autologous transplantation, the patient's own cells or tissues are used to replace or repair damaged or diseased ones. This reduces the risk of rejection and eliminates the need for immunosuppressive drugs, which are required in allogeneic transplants to prevent the body from attacking the foreign tissue.

Examples of autologous transplantation include:

* Autologous bone marrow or stem cell transplantation, where stem cells are removed from the patient's blood or bone marrow, stored and then reinfused back into the same individual after high-dose chemotherapy or radiation therapy to treat cancer.
* Autologous skin grafting, where a piece of skin is taken from one part of the body and transplanted to another area on the same person.
* Autologous chondrocyte implantation, where cartilage cells are harvested from the patient's own knee, cultured in a laboratory and then implanted back into the knee to repair damaged cartilage.

I'm sorry for any confusion, but "Myeloablative Agonists" is not a recognized medical term. Myeloablation is a medical process that involves destroying or damaging the bone marrow, often as part of a preparatory regimen before a stem cell transplant. Agonists are substances that bind to receptors and activate them, causing a response in the body. However, combining these two terms doesn't form a recognized medical concept. If you have any questions about myeloablation or agonists individually, I'd be happy to help clarify those concepts!

Carmustine is a chemotherapy drug used to treat various types of cancer, including brain tumors, multiple myeloma, and Hodgkin's lymphoma. It belongs to a class of drugs called alkylating agents, which work by damaging the DNA in cancer cells, preventing them from dividing and growing.

Carmustine is available as an injectable solution that is administered intravenously (into a vein) or as implantable wafers that are placed directly into the brain during surgery. The drug can cause side effects such as nausea, vomiting, hair loss, and low blood cell counts, among others. It may also increase the risk of certain infections and bleeding complications.

As with all chemotherapy drugs, carmustine can have serious and potentially life-threatening side effects, and it should only be administered under the close supervision of a qualified healthcare professional. Patients receiving carmustine treatment should be closely monitored for signs of toxicity and other adverse reactions.

Antineoplastic combined chemotherapy protocols refer to a treatment plan for cancer that involves the use of more than one antineoplastic (chemotherapy) drug given in a specific sequence and schedule. The combination of drugs is used because they may work better together to destroy cancer cells compared to using a single agent alone. This approach can also help to reduce the likelihood of cancer cells becoming resistant to the treatment.

The choice of drugs, dose, duration, and frequency are determined by various factors such as the type and stage of cancer, patient's overall health, and potential side effects. Combination chemotherapy protocols can be used in various settings, including as a primary treatment, adjuvant therapy (given after surgery or radiation to kill any remaining cancer cells), neoadjuvant therapy (given before surgery or radiation to shrink the tumor), or palliative care (to alleviate symptoms and prolong survival).

It is important to note that while combined chemotherapy protocols can be effective in treating certain types of cancer, they can also cause significant side effects, including nausea, vomiting, hair loss, fatigue, and an increased risk of infection. Therefore, patients undergoing such treatment should be closely monitored and managed by a healthcare team experienced in administering chemotherapy.

Amyloidosis is a medical condition characterized by the abnormal accumulation of insoluble proteins called amyloid in various tissues and organs throughout the body. These misfolded protein deposits can disrupt the normal function of affected organs, leading to a range of symptoms depending on the location and extent of the amyloid deposition.

There are different types of amyloidosis, classified based on the specific proteins involved:

1. Primary (AL) Amyloidosis: This is the most common form, accounting for around 80% of cases. It results from the overproduction and misfolding of immunoglobulin light chains, typically by clonal plasma cells in the bone marrow. The amyloid deposits can affect various organs, including the heart, kidneys, liver, and nervous system.
2. Secondary (AA) Amyloidosis: This form is associated with chronic inflammatory diseases, such as rheumatoid arthritis, tuberculosis, or familial Mediterranean fever. The amyloid fibrils are composed of serum amyloid A protein (SAA), an acute-phase reactant produced during the inflammatory response. The kidneys are commonly affected in this type of amyloidosis.
3. Hereditary or Familial Amyloidosis: These forms are caused by genetic mutations that result in the production of abnormal proteins prone to misfolding and amyloid formation. Examples include transthyretin (TTR) amyloidosis, fibrinogen amyloidosis, and apolipoprotein AI amyloidosis. These forms can affect various organs, including the heart, nerves, and kidneys.
4. Dialysis-Related Amyloidosis: This form is seen in patients undergoing long-term dialysis for chronic kidney disease. The amyloid fibrils are composed of beta-2 microglobulin, a protein that accumulates due to impaired clearance during dialysis. The joints and bones are commonly affected in this type of amyloidosis.

The diagnosis of amyloidosis typically involves a combination of clinical evaluation, imaging studies, and tissue biopsy with the demonstration of amyloid deposition using special stains (e.g., Congo red). Treatment depends on the specific type and extent of organ involvement and may include supportive care, medications to target the underlying cause (e.g., chemotherapy, immunomodulatory agents), and organ transplantation in some cases.

Transplantation conditioning, also known as preparative regimen or immunoablative therapy, refers to the use of various treatments prior to transplantation of cells, tissues or organs. The main goal of transplantation conditioning is to suppress the recipient's immune system, allowing for successful engraftment and minimizing the risk of rejection of the donor tissue.

There are two primary types of transplantation conditioning: myeloablative and non-myeloablative.

1. Myeloablative conditioning is a more intensive regimen that involves the use of high-dose chemotherapy, radiation therapy or both. This approach eliminates not only immune cells but also stem cells in the bone marrow, requiring the recipient to receive a hematopoietic cell transplant (HCT) from the donor to reconstitute their blood and immune system.
2. Non-myeloablative conditioning is a less intensive regimen that primarily targets immune cells while sparing the stem cells in the bone marrow. This approach allows for mixed chimerism, where both recipient and donor immune cells coexist, reducing the risk of severe complications associated with myeloablative conditioning.

The choice between these two types of transplantation conditioning depends on various factors, including the type of transplant, patient's age, overall health, and comorbidities. Both approaches carry risks and benefits, and the decision should be made carefully by a multidisciplinary team of healthcare professionals in consultation with the patient.

Hematopoietic Stem Cell Transplantation (HSCT) is a medical procedure where hematopoietic stem cells (immature cells that give rise to all blood cell types) are transplanted into a patient. This procedure is often used to treat various malignant and non-malignant disorders affecting the hematopoietic system, such as leukemias, lymphomas, multiple myeloma, aplastic anemia, inherited immune deficiency diseases, and certain genetic metabolic disorders.

The transplantation can be autologous (using the patient's own stem cells), allogeneic (using stem cells from a genetically matched donor, usually a sibling or unrelated volunteer), or syngeneic (using stem cells from an identical twin).

The process involves collecting hematopoietic stem cells, most commonly from the peripheral blood or bone marrow. The collected cells are then infused into the patient after the recipient's own hematopoietic system has been ablated (or destroyed) using high-dose chemotherapy and/or radiation therapy. This allows the donor's stem cells to engraft, reconstitute, and restore the patient's hematopoietic system.

HSCT is a complex and potentially risky procedure with various complications, including graft-versus-host disease, infections, and organ damage. However, it offers the potential for cure or long-term remission in many patients with otherwise fatal diseases.

Prednisone is a synthetic glucocorticoid, which is a type of corticosteroid hormone. It is primarily used to reduce inflammation in various conditions such as asthma, allergies, arthritis, and autoimmune disorders. Prednisone works by mimicking the effects of natural hormones produced by the adrenal glands, suppressing the immune system's response and reducing the release of substances that cause inflammation.

It is available in oral tablet form and is typically prescribed to be taken at specific times during the day, depending on the condition being treated. Common side effects of prednisone include increased appetite, weight gain, mood changes, insomnia, and easy bruising. Long-term use or high doses can lead to more serious side effects such as osteoporosis, diabetes, cataracts, and increased susceptibility to infections.

Healthcare providers closely monitor patients taking prednisone for extended periods to minimize the risk of adverse effects. It is essential to follow the prescribed dosage regimen and not discontinue the medication abruptly without medical supervision, as this can lead to withdrawal symptoms or a rebound of the underlying condition.

Combined modality therapy (CMT) is a medical treatment approach that utilizes more than one method or type of therapy simultaneously or in close succession, with the goal of enhancing the overall effectiveness of the treatment. In the context of cancer care, CMT often refers to the combination of two or more primary treatment modalities, such as surgery, radiation therapy, and systemic therapies (chemotherapy, immunotherapy, targeted therapy, etc.).

The rationale behind using combined modality therapy is that each treatment method can target cancer cells in different ways, potentially increasing the likelihood of eliminating all cancer cells and reducing the risk of recurrence. The specific combination and sequence of treatments will depend on various factors, including the type and stage of cancer, patient's overall health, and individual preferences.

For example, a common CMT approach for locally advanced rectal cancer may involve preoperative (neoadjuvant) chemoradiation therapy, followed by surgery to remove the tumor, and then postoperative (adjuvant) chemotherapy. This combined approach allows for the reduction of the tumor size before surgery, increases the likelihood of complete tumor removal, and targets any remaining microscopic cancer cells with systemic chemotherapy.

It is essential to consult with a multidisciplinary team of healthcare professionals to determine the most appropriate CMT plan for each individual patient, considering both the potential benefits and risks associated with each treatment method.

Misonidazole is defined as a radiosensitizer drug, which is primarily used in the field of radiation oncology. It works by making cancer cells more sensitive to radiation therapy, thereby increasing the effectiveness of the treatment. Misonidazole is an nitroimidazole compound that gets reduced under hypoxic conditions (when there is a lack of oxygen) and forms free radicals, which can damage DNA and kill the cells.

It's important to note that misonidazole is not commonly used in current clinical practice due to its narrow therapeutic index and significant side effects, such as neurotoxicity. Other nitroimidazole radiosensitizers, such as nimorazole, have been developed and are more widely used because they have a lower risk of neurotoxicity.

Cyclophosphamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. This helps to stop the spread of cancer in the body. Cyclophosphamide is used to treat various types of cancer, including lymphoma, leukemia, multiple myeloma, and breast cancer. It can be given orally as a tablet or intravenously as an injection.

Cyclophosphamide can also have immunosuppressive effects, which means it can suppress the activity of the immune system. This makes it useful in treating certain autoimmune diseases, such as rheumatoid arthritis and lupus. However, this immunosuppression can also increase the risk of infections and other side effects.

Like all chemotherapy medications, cyclophosphamide can cause a range of side effects, including nausea, vomiting, hair loss, fatigue, and increased susceptibility to infections. It is important for patients receiving cyclophosphamide to be closely monitored by their healthcare team to manage these side effects and ensure the medication is working effectively.

Thalidomide is a pharmaceutical drug that was initially developed and marketed as a sedative and treatment for morning sickness in pregnant women. However, it was later found to cause severe birth defects when given during pregnancy, particularly damage to the limbs, ears, and eyes of the developing fetus. As a result, thalidomide was banned in many countries in the 1960s.

In recent years, thalidomide has been reintroduced as a treatment for certain medical conditions, including multiple myeloma (a type of cancer that affects plasma cells) and leprosy. It is also being studied as a potential treatment for other diseases, such as rheumatoid arthritis and Crohn's disease.

Thalidomide works by suppressing the immune system and inhibiting the formation of new blood vessels (angiogenesis). However, its use is tightly regulated due to its teratogenic effects, meaning it can cause birth defects if taken during pregnancy. Women who are pregnant or planning to become pregnant should not take thalidomide, and healthcare providers must follow strict guidelines when prescribing the drug to ensure that it is used safely and effectively.

Buthionine Sulfoximine (BSO) is a chemical compound that is known to inhibit the enzyme gamma-glutamylcysteine synthetase, which plays a crucial role in the production of glutathione, a powerful antioxidant in the body. By inhibiting this enzyme, BSO can deplete glutathione levels in cells, making it a useful tool in research to study the effects of glutathione depletion on various biological processes. It is often used in laboratory experiments and clinical trials for its potential therapeutic benefits in cancer treatment and other diseases associated with oxidative stress. However, its use as a therapeutic agent is still being investigated and has not yet been approved by regulatory agencies for widespread clinical use.

Methionine Sulfoximine (MSO) is not a medical term itself, but it is a compound that has been used in research and scientific studies. It's a stable analogue of the essential amino acid methionine, which can be found in some foods like sesame seeds, Brazil nuts, and fish.

Methionine Sulfoximine has been used in research to study the metabolism and transport of methionine in cells and organisms. It is also known for its ability to inhibit the enzyme cystathionine β-synthase (CBS), which plays a role in the metabolism of homocysteine, an amino acid associated with cardiovascular disease when present at high levels.

However, Methionine Sulfoximine is not used as a therapeutic agent or medication in humans due to its potential toxicity and lack of established clinical benefits.

Thiotepa is an antineoplastic (cancer-fighting) drug. It belongs to a class of medications called alkylating agents, which work by interfering with the DNA of cancer cells, preventing them from dividing and growing. Thiotepa is used in the treatment of various types of cancers, including breast, ovarian, and bladder cancer.

It may be administered intravenously (into a vein), intravesically (into the bladder), or intrathecally (into the spinal cord). The specific dosage and duration of treatment will depend on the type and stage of cancer being treated, as well as the patient's overall health status.

Like all chemotherapy drugs, thiotepa can have significant side effects, including nausea, vomiting, hair loss, and a weakened immune system. It is important for patients to discuss these potential risks with their healthcare provider before starting treatment.

Boronic acids are organic compounds that contain a boron atom bonded to two carbon atoms and a hydroxyl group. The general formula for a boronic acid is RB(OH)2, where R represents a organic group. Boronic acids are important reagents in organic synthesis and have been used in the preparation of pharmaceuticals, agrochemicals, and materials science. They can also form stable complexes with many diols and phenols, which is the basis for their use in the detection and quantification of sugars, as well as in the design of boronic acid-based drugs that target diseases such as cancer and diabetes.

Vincristine is an antineoplastic agent, specifically a vinca alkaloid. It is derived from the Madagascar periwinkle plant (Catharanthus roseus). Vincristine binds to tubulin, a protein found in microtubules, and inhibits their polymerization, which results in disruption of mitotic spindles leading to cell cycle arrest and apoptosis (programmed cell death). It is used in the treatment of various types of cancer including leukemias, lymphomas, and solid tumors. Common side effects include peripheral neuropathy, constipation, and alopecia.

I'm sorry for any confusion, but "pyrazines" is not a term commonly used in medical definitions. Pyrazines are actually a class of organic compounds that contain a ring made up of two nitrogen atoms and three carbon atoms. They are found in various foods and contribute to their flavors. If you have any questions about organic chemistry or food science, I'd be happy to try to help!

Alkylating agents are a class of chemotherapy drugs that work by alkylating, or adding an alkyl group to, DNA molecules. This process can damage the DNA and prevent cancer cells from dividing and growing. Alkylating agents are often used to treat various types of cancer, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, and solid tumors. Examples of alkylating agents include cyclophosphamide, melphalan, and chlorambucil. These drugs can have significant side effects, including nausea, vomiting, hair loss, and an increased risk of infection. They can also cause long-term damage to the heart, lungs, and reproductive system.

Busulfan is a chemotherapy medication used to treat various types of cancer, including chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML). It is an alkylating agent that works by damaging the DNA of cancer cells, which prevents them from dividing and growing.

The medical definition of Busulfan is:

A white crystalline powder used in chemotherapy to treat various types of cancer. Busulfan works by alkylating and cross-linking DNA, which inhibits DNA replication and transcription, leading to cell cycle arrest and apoptosis (programmed cell death) in rapidly dividing cells, including cancer cells. It is administered orally or intravenously and is often used in combination with other chemotherapy agents. Common side effects include nausea, vomiting, diarrhea, and bone marrow suppression, which can lead to anemia, neutropenia, thrombocytopenia, and increased susceptibility to infection. Long-term use of busulfan has been associated with pulmonary fibrosis, infertility, and an increased risk of secondary malignancies.

Chlorambucil is a medication that belongs to a class of drugs called alkylating agents. It is an antineoplastic drug, which means it is used to treat cancer. Chlorambucil works by interfering with the DNA in cells, which prevents them from dividing and growing. This makes it useful for treating certain types of cancer, such as chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma.

Chlorambucil is available in tablet form and is typically taken once a day. It is important to take chlorambucil exactly as directed by your healthcare provider, as the dosage and schedule will depend on your individual medical condition and response to treatment.

Like all medications, chlorambucil can cause side effects. Common side effects of chlorambucil include nausea, vomiting, diarrhea, and loss of appetite. It can also cause more serious side effects, such as a decrease in the number of white blood cells (which can increase the risk of infection), anemia (low red blood cell count), and thrombocytopenia (low platelet count). Chlorambucil may also increase the risk of certain types of cancer, such as acute myeloid leukemia (AML) and solid tumors.

It is important to discuss the potential risks and benefits of chlorambucil with your healthcare provider before starting treatment. They can help you understand the potential side effects and how to manage them, as well as any other precautions you should take while taking this medication.

The term "extremities" in a medical context refers to the most distant parts of the body, including the hands and feet (both fingers and toes), as well as the arms and legs. These are the farthest parts from the torso and head. Medical professionals may examine a patient's extremities for various reasons, such as checking circulation, assessing nerve function, or looking for injuries or abnormalities.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Drug synergism is a pharmacological concept that refers to the interaction between two or more drugs, where the combined effect of the drugs is greater than the sum of their individual effects. This means that when these drugs are administered together, they produce an enhanced therapeutic response compared to when they are given separately.

Drug synergism can occur through various mechanisms, such as:

1. Pharmacodynamic synergism - When two or more drugs interact with the same target site in the body and enhance each other's effects.
2. Pharmacokinetic synergism - When one drug affects the metabolism, absorption, distribution, or excretion of another drug, leading to an increased concentration of the second drug in the body and enhanced therapeutic effect.
3. Physiochemical synergism - When two drugs interact physically, such as when one drug enhances the solubility or permeability of another drug, leading to improved absorption and bioavailability.

It is important to note that while drug synergism can result in enhanced therapeutic effects, it can also increase the risk of adverse reactions and toxicity. Therefore, healthcare providers must carefully consider the potential benefits and risks when prescribing combinations of drugs with known or potential synergistic effects.

Drug resistance, also known as antimicrobial resistance, is the ability of a microorganism (such as bacteria, viruses, fungi, or parasites) to withstand the effects of a drug that was originally designed to inhibit or kill it. This occurs when the microorganism undergoes genetic changes that allow it to survive in the presence of the drug. As a result, the drug becomes less effective or even completely ineffective at treating infections caused by these resistant organisms.

Drug resistance can develop through various mechanisms, including mutations in the genes responsible for producing the target protein of the drug, alteration of the drug's target site, modification or destruction of the drug by enzymes produced by the microorganism, and active efflux of the drug from the cell.

The emergence and spread of drug-resistant microorganisms pose significant challenges in medical treatment, as they can lead to increased morbidity, mortality, and healthcare costs. The overuse and misuse of antimicrobial agents, as well as poor infection control practices, contribute to the development and dissemination of drug-resistant strains. To address this issue, it is crucial to promote prudent use of antimicrobials, enhance surveillance and monitoring of resistance patterns, invest in research and development of new antimicrobial agents, and strengthen infection prevention and control measures.

Stem cell transplantation is a medical procedure where stem cells, which are immature and unspecialized cells with the ability to differentiate into various specialized cell types, are introduced into a patient. The main purpose of this procedure is to restore the function of damaged or destroyed tissues or organs, particularly in conditions that affect the blood and immune systems, such as leukemia, lymphoma, aplastic anemia, and inherited metabolic disorders.

There are two primary types of stem cell transplantation: autologous and allogeneic. In autologous transplantation, the patient's own stem cells are collected, stored, and then reinfused back into their body after high-dose chemotherapy or radiation therapy to destroy the diseased cells. In allogeneic transplantation, stem cells are obtained from a donor (related or unrelated) whose human leukocyte antigen (HLA) type closely matches that of the recipient.

The process involves several steps: first, the patient undergoes conditioning therapy to suppress their immune system and make space for the new stem cells. Then, the harvested stem cells are infused into the patient's bloodstream, where they migrate to the bone marrow and begin to differentiate and produce new blood cells. This procedure requires close monitoring and supportive care to manage potential complications such as infections, graft-versus-host disease, and organ damage.

Semustine is not a medical term itself, but it's a brand name for the chemical compound called lomustine. Here is the medical definition of Lomustine:

Lomustine: A nitrosourea alkylating agent used in cancer chemotherapy. It is classified as an antineoplastic agent and works by preventing the growth of cancer cells through inhibiting DNA replication. Lomustine is used to treat various types of cancers, including Hodgkin's lymphoma, brain tumors, and non-Hodgkin's lymphoma. Common side effects include nausea, vomiting, and bone marrow suppression leading to anemia, leukopenia, and thrombocytopenia.

Melanoma is defined as a type of cancer that develops from the pigment-containing cells known as melanocytes. It typically occurs in the skin but can rarely occur in other parts of the body, including the eyes and internal organs. Melanoma is characterized by the uncontrolled growth and multiplication of melanocytes, which can form malignant tumors that invade and destroy surrounding tissue.

Melanoma is often caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds, but it can also occur in areas of the body not exposed to the sun. It is more likely to develop in people with fair skin, light hair, and blue or green eyes, but it can affect anyone, regardless of their skin type.

Melanoma can be treated effectively if detected early, but if left untreated, it can spread to other parts of the body and become life-threatening. Treatment options for melanoma include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, depending on the stage and location of the cancer. Regular skin examinations and self-checks are recommended to detect any changes or abnormalities in moles or other pigmented lesions that may indicate melanoma.

'Rats, Nude' is not a standard medical term or condition. The term 'nude' in the context of laboratory animals like rats usually refers to a strain of rats that are hairless due to a genetic mutation. This can make them useful for studies involving skin disorders, wound healing, and other conditions where fur might interfere with observations or procedures. However, 'Rats, Nude' is not a recognized or established term in medical literature or taxonomy.

Bone marrow transplantation (BMT) is a medical procedure in which damaged or destroyed bone marrow is replaced with healthy bone marrow from a donor. Bone marrow is the spongy tissue inside bones that produces blood cells. The main types of BMT are autologous, allogeneic, and umbilical cord blood transplantation.

In autologous BMT, the patient's own bone marrow is used for the transplant. This type of BMT is often used in patients with lymphoma or multiple myeloma who have undergone high-dose chemotherapy or radiation therapy to destroy their cancerous bone marrow.

In allogeneic BMT, bone marrow from a genetically matched donor is used for the transplant. This type of BMT is often used in patients with leukemia, lymphoma, or other blood disorders who have failed other treatments.

Umbilical cord blood transplantation involves using stem cells from umbilical cord blood as a source of healthy bone marrow. This type of BMT is often used in children and adults who do not have a matched donor for allogeneic BMT.

The process of BMT typically involves several steps, including harvesting the bone marrow or stem cells from the donor, conditioning the patient's body to receive the new bone marrow or stem cells, transplanting the new bone marrow or stem cells into the patient's body, and monitoring the patient for signs of engraftment and complications.

BMT is a complex and potentially risky procedure that requires careful planning, preparation, and follow-up care. However, it can be a life-saving treatment for many patients with blood disorders or cancer.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

Remission induction is a treatment approach in medicine, particularly in the field of oncology and hematology. It refers to the initial phase of therapy aimed at reducing or eliminating the signs and symptoms of active disease, such as cancer or autoimmune disorders. The primary goal of remission induction is to achieve a complete response (disappearance of all detectable signs of the disease) or a partial response (a decrease in the measurable extent of the disease). This phase of treatment is often intensive and may involve the use of multiple drugs or therapies, including chemotherapy, immunotherapy, or targeted therapy. After remission induction, patients may receive additional treatments to maintain the remission and prevent relapse, known as consolidation or maintenance therapy.

Peripheral Blood Stem Cell Transplantation (PBSCT) is a medical procedure that involves the transplantation of stem cells, which are immature cells found in the bone marrow that can develop into different types of blood cells. In PBSCT, these stem cells are collected from the peripheral blood instead of directly from the bone marrow.

The process begins with mobilization, where a growth factor medication is given to the donor to stimulate the release of stem cells from the bone marrow into the peripheral blood. After several days, the donor's blood is then removed through a procedure called apheresis, where the stem cells are separated and collected while the remaining blood components are returned to the donor.

The collected stem cells are then infused into the recipient's bloodstream, where they migrate to the bone marrow and begin to repopulate, leading to the production of new blood cells. This procedure is often used as a treatment for various malignant and non-malignant disorders, such as leukemia, lymphoma, multiple myeloma, and aplastic anemia.

PBSCT offers several advantages over traditional bone marrow transplantation, including faster engraftment, lower risk of graft failure, and reduced procedure-related morbidity. However, it also has its own set of challenges, such as the potential for increased incidence of chronic graft-versus-host disease (GVHD) and the need for more stringent HLA matching between donor and recipient.

Dexamethasone is a type of corticosteroid medication, which is a synthetic version of a natural hormone produced by the adrenal glands. It is often used to reduce inflammation and suppress the immune system in a variety of medical conditions, including allergies, asthma, rheumatoid arthritis, and certain skin conditions.

Dexamethasone works by binding to specific receptors in cells, which triggers a range of anti-inflammatory effects. These include reducing the production of chemicals that cause inflammation, suppressing the activity of immune cells, and stabilizing cell membranes.

In addition to its anti-inflammatory effects, dexamethasone can also be used to treat other medical conditions, such as certain types of cancer, brain swelling, and adrenal insufficiency. It is available in a variety of forms, including tablets, liquids, creams, and injectable solutions.

Like all medications, dexamethasone can have side effects, particularly if used for long periods of time or at high doses. These may include mood changes, increased appetite, weight gain, acne, thinning skin, easy bruising, and an increased risk of infections. It is important to follow the instructions of a healthcare provider when taking dexamethasone to minimize the risk of side effects.

Lomustine is a medical term for a specific antineoplastic agent, which is a type of medication used to treat cancer. It's a nitrosourea compound that is classified as an alkylating agent, meaning it works by preventing the reproduction of cancer cells. Lomustine is used in the treatment of various types of cancer, including brain tumors, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. It's usually administered orally in the form of a capsule. As with any medication, it can have side effects, which can include nausea, vomiting, and lowered blood cell counts.

Etoposide is a chemotherapy medication used to treat various types of cancer, including lung cancer, testicular cancer, and certain types of leukemia. It works by inhibiting the activity of an enzyme called topoisomerase II, which is involved in DNA replication and transcription. By doing so, etoposide can interfere with the growth and multiplication of cancer cells.

Etoposide is often administered intravenously in a hospital or clinic setting, although it may also be given orally in some cases. The medication can cause a range of side effects, including nausea, vomiting, hair loss, and an increased risk of infection. It can also have more serious side effects, such as bone marrow suppression, which can lead to anemia, bleeding, and a weakened immune system.

Like all chemotherapy drugs, etoposide is not without risks and should only be used under the close supervision of a qualified healthcare provider. It is important for patients to discuss the potential benefits and risks of this medication with their doctor before starting treatment.

Drug screening assays for antitumor agents are laboratory tests used to identify and evaluate the effectiveness of potential drugs or compounds that can inhibit the growth of tumor cells or induce their death. These assays are typically performed in vitro (in a test tube or petri dish) using cell cultures of various types of cancer cells.

The assays measure different parameters such as cell viability, proliferation, apoptosis (programmed cell death), and cytotoxicity to determine the ability of the drug to kill or inhibit the growth of tumor cells. The results of these assays can help researchers identify promising antitumor agents that can be further developed for clinical use in cancer treatment.

There are different types of drug screening assays for antitumor agents, including high-throughput screening (HTS) assays, which allow for the rapid and automated testing of a large number of compounds against various cancer cell lines. Other types of assays include phenotypic screening assays, target-based screening assays, and functional screening assays, each with its own advantages and limitations.

Overall, drug screening assays for antitumor agents play a critical role in the development of new cancer therapies by providing valuable information on the activity and safety of potential drugs, helping to identify effective treatments and reduce the time and cost associated with bringing new drugs to market.

Doxorubicin is a type of chemotherapy medication known as an anthracycline. It works by interfering with the DNA in cancer cells, which prevents them from growing and multiplying. Doxorubicin is used to treat a wide variety of cancers, including leukemia, lymphoma, breast cancer, lung cancer, ovarian cancer, and many others. It may be given alone or in combination with other chemotherapy drugs.

Doxorubicin is usually administered through a vein (intravenously) and can cause side effects such as nausea, vomiting, hair loss, mouth sores, and increased risk of infection. It can also cause damage to the heart muscle, which can lead to heart failure in some cases. For this reason, doctors may monitor patients' heart function closely while they are receiving doxorubicin treatment.

It is important for patients to discuss the potential risks and benefits of doxorubicin therapy with their healthcare provider before starting treatment.

Nitrogen mustard compounds are a group of chemical agents that have been used historically as chemotherapy drugs and also have potential as military chemical warfare agents. They are alkylating agents, which means they work by modifying DNA in such a way that it can no longer replicate properly, leading to cell death.

In the medical context, nitrogen mustard compounds are used to treat certain types of cancer, including Hodgkin's lymphoma and non-Hodgkin's lymphoma. They may also be used to treat chronic lymphocytic leukemia, multiple myeloma, and other cancers.

The most common nitrogen mustard compounds used in medicine are mechlorethamine, cyclophosphamide, ifosfamide, and melphalan. These drugs are typically administered intravenously or orally, and their use is carefully monitored to minimize side effects such as nausea, vomiting, hair loss, and suppression of the immune system.

It's worth noting that nitrogen mustard compounds can also be highly toxic and dangerous if used as chemical warfare agents. They can cause severe respiratory, skin, and eye damage, as well as potentially fatal systemic effects.

Whole-Body Irradiation (WBI) is a medical procedure that involves the exposure of the entire body to a controlled dose of ionizing radiation, typically used in the context of radiation therapy for cancer treatment. The purpose of WBI is to destroy cancer cells or suppress the immune system prior to a bone marrow transplant. It can be delivered using various sources of radiation, such as X-rays, gamma rays, or electrons, and is carefully planned and monitored to minimize harm to healthy tissues while maximizing the therapeutic effect on cancer cells. Potential side effects include nausea, vomiting, fatigue, and an increased risk of infection due to decreased white blood cell counts.

Vidarabine is an antiviral medication used to treat herpes simplex infections, particularly severe cases such as herpes encephalitis (inflammation of the brain caused by the herpes simplex virus). It works by interfering with the DNA replication of the virus.

In medical terms, vidarabine is a nucleoside analogue that is phosphorylated intracellularly to the active form, vidarabine triphosphate. This compound inhibits viral DNA polymerase and incorporates into viral DNA, causing termination of viral DNA synthesis.

Vidarabine was previously used as an injectable medication but has largely been replaced by more modern antiviral drugs such as acyclovir due to its greater efficacy and lower toxicity.

Hyperthermia, induced, is a medically controlled increase in core body temperature beyond the normal range (36.5-37.5°C or 97.7-99.5°F) to a target temperature typically between 38-42°C (100.4-107.6°F). This therapeutic intervention is used in various medical fields, including oncology and critical care medicine. Induced hyperthermia can be achieved through different methods such as whole-body heating or localized heat application, often combined with chemotherapy or radiation therapy to enhance treatment efficacy.

In the context of oncology, hyperthermia is used as a sensitizer for cancer treatments by increasing blood flow to tumors, enhancing drug delivery, and directly damaging cancer cells through protein denaturation and apoptosis at higher temperatures. In critical care settings, induced hyperthermia may be applied in therapeutic hypothermia protocols to protect the brain after cardiac arrest or other neurological injuries by decreasing metabolic demand and reducing oxidative stress.

It is essential to closely monitor patients undergoing induced hyperthermia for potential adverse effects, including cardiovascular instability, electrolyte imbalances, and infections, and manage these complications promptly to ensure patient safety during the procedure.

Disease-free survival (DFS) is a term used in medical research and clinical practice, particularly in the field of oncology. It refers to the length of time after primary treatment for a cancer during which no evidence of the disease can be found. This means that the patient shows no signs or symptoms of the cancer, and any imaging studies or other tests do not reveal any tumors or other indications of the disease.

DFS is often used as an important endpoint in clinical trials to evaluate the effectiveness of different treatments for cancer. By measuring the length of time until the cancer recurs or a new cancer develops, researchers can get a better sense of how well a particular treatment is working and whether it is improving patient outcomes.

It's important to note that DFS is not the same as overall survival (OS), which refers to the length of time from primary treatment until death from any cause. While DFS can provide valuable information about the effectiveness of cancer treatments, it does not necessarily reflect the impact of those treatments on patients' overall survival.

The Alfaxalone Alfadolone Mixture is a veterinary anesthetic agent, which contains two active ingredients: alfaxalone and alfadolone. Both are neuroactive steroids that depress the central nervous system, leading to sedation, muscle relaxation, and eventually anesthesia.

The mixture is used for induction and maintenance of anesthesia in various animal species, including dogs, cats, and horses. It provides smooth induction and rapid recovery from anesthesia, making it a popular choice among veterinarians. However, as with any anesthetic agent, there are potential risks and side effects associated with its use, such as respiratory depression, cardiovascular depression, and apnea. Proper dosing, monitoring, and management are essential to ensure the safety and efficacy of this anesthetic agent in veterinary medicine.

Flunarizine is a medication that belongs to the class of drugs known as calcium channel blockers. It is primarily used in the prevention of migraine headaches and to treat vertigo (a spinning sensation) associated with various conditions such as Meniere's disease. Flunarizine works by blocking calcium channels, which reduces the influx of calcium ions into cells. This action leads to relaxation of smooth muscle, decreased neurotransmitter release, and inhibition of platelet aggregation, ultimately helping to prevent migraines and alleviate symptoms of vertigo. It is available in the form of tablets for oral administration.

Stomatitis is a medical term that refers to inflammation of the mucous membrane of any of the soft tissues in the mouth, including the lips, gums, tongue, palate, and cheek lining. It can cause discomfort, pain, and sores or lesions in the mouth. Stomatitis may result from a variety of causes, such as infection, injury, allergic reaction, or systemic diseases. Treatment depends on the underlying cause and may include medications, mouth rinses, or changes in oral hygiene practices.

Cell survival refers to the ability of a cell to continue living and functioning normally, despite being exposed to potentially harmful conditions or treatments. This can include exposure to toxins, radiation, chemotherapeutic drugs, or other stressors that can damage cells or interfere with their normal processes.

In scientific research, measures of cell survival are often used to evaluate the effectiveness of various therapies or treatments. For example, researchers may expose cells to a particular drug or treatment and then measure the percentage of cells that survive to assess its potential therapeutic value. Similarly, in toxicology studies, measures of cell survival can help to determine the safety of various chemicals or substances.

It's important to note that cell survival is not the same as cell proliferation, which refers to the ability of cells to divide and multiply. While some treatments may promote cell survival, they may also inhibit cell proliferation, making them useful for treating diseases such as cancer. Conversely, other treatments may be designed to specifically target and kill cancer cells, even if it means sacrificing some healthy cells in the process.

Nitroimidazoles are a class of antibiotic drugs that contain a nitro group (-NO2) attached to an imidazole ring. These medications have both antiprotozoal and antibacterial properties, making them effective against a range of anaerobic organisms, including bacteria and parasites. They work by being reduced within the organism, which leads to the formation of toxic radicals that interfere with DNA function and ultimately kill the microorganism.

Some common examples of nitroimidazoles include:

* Metronidazole: used for treating infections caused by anaerobic bacteria and protozoa, such as bacterial vaginosis, amebiasis, giardiasis, and pseudomembranous colitis.
* Tinidazole: similar to metronidazole, it is used to treat various infections caused by anaerobic bacteria and protozoa, including trichomoniasis, giardiasis, and amebiasis.
* Secnidazole: another medication in this class, used for the treatment of bacterial vaginosis, trichomoniasis, and amebiasis.

Nitroimidazoles are generally well-tolerated, but side effects can include gastrointestinal symptoms like nausea, vomiting, or diarrhea. Rare but serious side effects may include peripheral neuropathy (nerve damage) and central nervous system toxicity, particularly with high doses or long-term use. It is essential to follow the prescribed dosage and duration closely to minimize potential risks while ensuring effective treatment.

I'm sorry for any confusion, but "Sarcoma, Experimental" is not a recognized medical term or definition. Sarcomas are a type of cancer that develop in the body's connective tissues, such as bones, muscles, tendons, cartilage, and fat. There are many different types of sarcomas, classified based on the specific type of tissue they originate from.

Experimental, on the other hand, refers to something that is being tested or tried out for the first time, typically as part of a scientific experiment or clinical trial. In the context of cancer treatment, an experimental therapy might refer to a new drug, procedure, or device that is still being studied in clinical trials to determine its safety and effectiveness.

Therefore, "Sarcoma, Experimental" could potentially refer to a clinical trial or research study involving a new treatment for sarcoma, but it would not be a medical definition in and of itself. If you have any specific questions about sarcomas or experimental treatments, I would recommend consulting with a healthcare professional or medical researcher for more accurate information.

Histamine agents are substances that can either increase or decrease the level or action of histamine in the body. Histamine is a chemical mediator released by mast cells and basophils in response to allergies, inflammation, or injury. It causes various symptoms such as itching, sneezing, runny nose, and wheal and flare reactions in the skin.

Histamine-releasing agents are substances that can trigger the release of histamine from mast cells and basophils. Examples include certain medications (e.g., opioids, vancomycin), physical stimuli (e.g., heat, exercise), and venoms (e.g., bee stings).

Histamine-inhibiting agents are substances that can block the action of histamine or prevent its release from mast cells and basophils. Examples include antihistamines, which bind to histamine receptors and prevent histamine from exerting its effects, and mast cell stabilizers, which prevent the degranulation of mast cells and the subsequent release of histamine and other mediators.

Histamine-enhancing agents are substances that can increase the level or action of histamine in the body. Examples include histamine agonists, which mimic the effects of histamine by binding to its receptors, and histamine precursors, which provide the building blocks for the synthesis of histamine.

Overall, histamine agents have important clinical implications in the management of allergies, inflammation, and other conditions associated with histamine release or action.

"Alkeran- melphalan tablet, film coated". DailyMed. 18 November 2019. Retrieved 23 April 2022. "Evomela- melphalan injection, ... Melphalan was approved for medical use in the United States in 1964. It is on the World Health Organization's List of Essential ... Melphalan belongs to the class of nitrogen mustard alkylating agents. It works by interfering with the creation of DNA and RNA ... The applicant for this medicinal product is Adienne S.r.l. S.U. Melphalan was approved for medical use in the European Union in ...
... is a peptidase enhanced cytotoxic (PEnC) with a targeted delivery within tumor cells of melphalan, a ... Compared to melphalan, melphalan flufenamide exhibits significantly higher in vitro and in vivo activity in several models of ... This suggests that melphalan flufenamide is rapidly and widely distributed to extravasal tissues, in which melphalan is formed ... Melphalan flufenamide was approved for medical use in the European Union in August 2022. Melphalan flufenamide is the ...
Examples include melphalan and chlorambucil. The following three groups are almost always considered "classical". Nitrogen ... Uramustine or uracil mustard Melphalan Chlorambucil Ifosfamide Bendamustine Nitrosoureas Carmustine Lomustine Streptozocin ...
Defty, CL; Marsden, JR (2012). "Melphalan in regional chemotherapy for locally recurrent metastatic melanoma". Current Topics ...
Most chemotherapy is delivered intravenously, although a number of agents can be administered orally (e.g., melphalan, busulfan ... Dexamethasone along with either bortezomib or melphalan is commonly used as a treatment for AL amyloidosis. Recently, ... Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas ... melphalan) including CDDP could be reversed at least partially by the addition of heat. Chemotherapy is used in veterinary ...
Other nitrogen mustards developed include cyclophosphamide, chlorambucil, uramustine, melphalan, and bendamustine. Bendamustine ...
Treatment with bortezomib, melphalan, and prednisone had an estimated overall survival of 83% at 30 months, lenalidomide plus ... For these people, the standard of care has been chemotherapy with melphalan and prednisone. Recent studies among this ... August 2008). "Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma". The New England Journal of ... such as melphalan, cyclophosphamide, thalidomide, or dexamethasone, alone or in combination), and a second ASCT. Later in the ...
Meiotic inter-strand DNA damages caused by melphalan can escape paternal repair and cause chromosomal aberrations in the zygote ... Melphalan is a bifunctional alkylating agent frequently used in chemotherapy. ...
The drugs for which it receives royalties include Kyprolis, Promacta, Melphalan and Baxdela. As of 2015, Ligand Pharmaceuticals ...
"VELCADE as Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone". Millennium Corporate ...
The EWOG-MDS study also involves cyclophosphamide and melphalan in its conditioning regimen. Post transplant management: ...
Improvement has also been noted with autologous stem cell transplantation, and chemotherapy with melphalan. Chahin N, Selcen D ...
"Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma", News-Medical.Net, 20 July 2015, retrieved 6 ... NASDAQ: DCTH) a specialty pharmaceutical and medical device company manufactures melphalan. By 2011 the oral medications for ... melphalan (trade name Alkeran), busulfan, capecitabine). Delcath Systems, Inc. ( ...
EMA has also approved it to treat MM in combination with prednisone and/or melphalan. Orphan indications by the FDA include ...
High-dose melphalan in conjunction with autologous stem cell transplantation has been used in some patients. A regimen of ...
The four-drug combination helped in the increased overall remission rate, but was more toxigenic than melphalan. The four-drug ... regimen is more effective than melphalan in the management of advanced ovarian adenocarcinoma. ST8 suppression of ...
... and melphalan. There needs to be more research done to determine appropriate dosing and combinations of these drugs to advance ...
In 2009, Aspen purchased the rights to market Melphalan and several other cancer drugs from GSK, such as levothyroxine, ... The investigation was conducted due to rising prices for five drugs (chlorambucil, melphalan, mercaptopurine, tioguanine and ...
... is used as a first-line treatment for multiple myeloma in combination with dexamethasone or with melphalan and ... It was also evaluated whether thalidomide can be combined with melphalan and prednisone for patients with multiple myeloma. ... including doxorubicin and melphalan) concurrently. Thalidomide may interfere with various contraceptives, and hence it is ...
... melphalan, chlorambucil and chlormethine. Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and ...
"Ice-cream used as cryotherapy during high-dose melphalan conditioning reduces oral mucositis after autologous hematopoietic ...
... with neutrophil and platelet recovery in patients receiving autologous marrow transplantation after high-dose melphalan ...
People were randomized to receive either nine cycles of oral melphalan (M) plus prednisone (P) or MP plus bortezomib. People ... It was seen that bortezomib plus lenalidomide plus dexamethasone as well as bortezomib plus melphalan and prednisone may result ...
Hematological response rates to the dexamethasone/melphalan regimens have been reported to be in the 80% range with ... a corticosteroid such as dexamethasone plus an alkylating agents such as melphalan. Dosage regimens are selected on the basis ... neurological response rates approaching 100%. Patients successfully treated with the high-dose dexamethasone/melphalan regimen ...
... melphalan, chlorambucil and chlormethine. Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and ...
... polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan". ...
... polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan". ...
It has been reported that clearance of lesions can be done with melphalan and cyclophosphamide alone or in combination with ...
Use under this protocol, usually with fludarabine and melphalan, was developed by oncologists at the University of Texas MD ...
... and melphalan (Alkeran). In 1952 the ICR's Eric Boyland had proposed that certain chemicals that cause cancer (carcinogens) ...
"Alkeran- melphalan tablet, film coated". DailyMed. 18 November 2019. Retrieved 23 April 2022. "Evomela- melphalan injection, ... Melphalan was approved for medical use in the United States in 1964. It is on the World Health Organizations List of Essential ... Melphalan belongs to the class of nitrogen mustard alkylating agents. It works by interfering with the creation of DNA and RNA ... The applicant for this medicinal product is Adienne S.r.l. S.U. Melphalan was approved for medical use in the European Union in ...
Melphalan: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Melphalan is used to treat multiple myeloma (a type of cancer of the bone marrow). Melphalan is also used to treat a certain ... Before taking melphalan,. *tell your doctor and pharmacist if you are allergic to melphalan, any other medications, or any of ... Melphalan may increase the risk that you will develop other cancers. Talk with your doctor about the risks of taking melphalan. ...
This page contains brief information about melphalan hydrochloride and a collection of links to more information about the use ... Melphalan hydrochloride is an injection form of melphalan. Melphalan also comes as a tablet that is taken by mouth. For more ... Melphalan hydrochloride is approved to treat:. *Multiple myeloma. This use is approved for the Evomela brand of melphalan ... More About Melphalan Hydrochloride. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names ...
MELPHALAN HYDROCHLORIDE (UNII: 1VXP4V453T) (MELPHALAN - UNII:Q41OR9510P) MELPHALAN. 50 mg in 10 mL. ... Each single-use vial contains melphalan hydrochloride equivalent to 50 mg melphalan and 20 mg povidone. Melphalan Hydrochloride ... Melphalan doses in each arm were:. Arm 1: Oral melphalan 0.15 mg/kg/day x 7 followed by 0.05 mg/kg/day when WBC began to rise. ... Mean (±SD) peak melphalan plasma concentrations in myeloma patients given intravenous melphalan at doses of 10 or 20 mg/m 2 ...
Find patient medical information for melphalan oral on WebMD including its uses, side effects and safety, interactions, ... Melphalan Tablet - Uses, Side Effects, and More Common Brand(S): Alkeran. Generic Name(S): melphalan. ... Although melphalan is used to treat cancer, it may rarely increase your risk of developing other cancers. Also, melphalan may ... You should not become pregnant while you are using melphalan. Melphalan may harm an unborn baby. If you become pregnant, talk ...
... melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without daratumumab. ... Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma N Engl J Med. 2018 Feb 8;378(6):518-528. doi: ... Background: The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed ... melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without daratumumab. ...
Melphalan Tablets. Products Affected - Description. * *Alkeran oral tablet, Apo-Pharma, 2 mg, glass bottle, 50 count, NDC 52609 ... Melphalan oral tablet, Alvogen, 2 mg, bottle, 50 count, NDC 47781-0200-50 - discontinued ...
Melphalan) drug information. Find its price or cost, dose, when to use, how to use, side effects, adverse effects, substitutes ... Melphalan (Alkacel (5 mg)) is a chemotherapy agent, prescribed for multiple myeloma, melanoma, and ovarian carcinoma. It stops ...
Melphalan injection is also used to treat uveal melanoma (eye cancer) that has spread to the liver and cannot be removed by ... Evomela®, Alkeran®, and Melphalan injection are to be given only by or under the direct supervision of your doctor. Hepzato® ... Melphalan injection is used to treat multiple myeloma (bone marrow cancer) before receiving a stem cell transplant ( ... Since the growth of normal cells may also be affected by melphalan, other unwanted effects will also occur. Before you begin ...
Hazard 2* P 0 B 0 T 2* Risk Cannot be excluded. The data on hazard and risk are based on previous environmental information on Fass.se. Environmental information is missing on fass.se (2019-03-13). It is voluntary for manufacturers to provide information about environmental impact on fass.se. ...
... melphalan), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, ... melphalan oral MELPHALAN - ORAL (MEL-fa-lan) COMMON BRAND NAME(S): Alkeran WARNING: Although melphalan is used to treat cancer ... encoded search term (melphalan (Evomela%2C Hepzato)) and melphalan (Evomela, Hepzato) What to Read Next on Medscape ... melphalan decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.. melphalan decreases ...
CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity ...
Because melphalan uptake is also mediated by LAT1, we used 18F-FDOPA PET as a surrogate reporter of melphalan therapy efficacy ... Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell ... Influx and efflux transport as determinants of melphalan cytotoxicity: resistance to melphalan in MDR1 overexpressing tumor ... which also mediates melphalan uptake, for imaging melphalan therapy response in a preclinical immunocompetent model of MM. ...
Pulmonary histopathologic changes associated with melphalan therapy. Cancer 1978 Sep;42;1239-45 1978 Sep ...
Although SIAC with a single agent (melphalan) has produced remarkable success,5 ,6 ,9 it does not succeed in all patients, and ... In the three-drug therapy, dose ranges were 2.5-7.5 mg for melphalan, 0.3-0.6 mg for topotecan, and 25-50 mg for carboplatin, ... There were a total of 61 three-drug (melphalan, carboplatin, and topotecan) infusion sessions. The mean number of three-drug ... Topotecan and carboplatin were chosen for a three-drug combination with melphalan because they have been used successfully as ...
High-dose melphalan and autologous stem cell transplantation (HDM/ASCT) is widely used in immunoglobulin light chain (AL) ... High-dose melphalan and autologous stem cell transplantation (HDM/ASCT) is widely used in immunoglobulin light chain (AL) ... Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from ... article{acb5f792-e674-4315-9cc6-78fbec130c7a, abstract = {{,p,High-dose melphalan and autologous stem cell transplantation (HDM ...
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) ... with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan ... Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Clinical ... Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment ...
Tumour necrosis factor (TNF) α and melphalan-based isolated limb perfusion (TM-ILP) is a limb-saving treatment modality for ... Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis.. ... Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis. ...
20.000+ innovative pharmaceutical reference standards
"Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma." Ann Surg Oncol 22 ... "Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma." Ann Surg Oncol, ... Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma.. Publication , ... Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. Ann Surg Oncol. ...
Melphalan is a drug belonging to the class of nitrogen mustard alkylating agents. It chemically alters through alkylation of ... Melphalan is a chemotherapy drug belonging to the class of nitrogen mustard alkylating agents. Melphalan chemically alters ... We have successfully synthesized the Melphalan Methyl Ester Hydrochloride. This will be of interest to pharmaceutical companies ...
Find information on Melphalan (Evomela) in Daviss Drug Guide including dosage, side effects, interactions, nursing ... "Melphalan." Daviss Drug Guide, 18th ed., F.A. Davis Company, 2023. Anesthesia Central, anesth.unboundmedicine.com/anesthesia/ ... view/Davis-Drug-Guide/51473/10.0/melphalan. Vallerand AHA, Sanoski CAC, Quiring CC. Melphalan. Daviss Drug Guide. F.A. Davis ... Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Melphalan. In Daviss Drug Guide (18th ed.). F.A. Davis Company. https ...
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell ... Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. ... analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood. 2010 Nov 11. ... Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2017 Dec 12. [QxMD MEDLINE Link]. [ ...
Melphalan medicine 2 mg and 5 mg at the best price. ... Melphalan Tablet Side Effects:. 1. Melphalan can inhibit bone ... Melphalan Tablet characteristics:. 1. Melphalan, an alkylating agent with a reputation for being beneficial in the treatment of ... Melphalan Tablets: Uses. 1. Melphalan is frequently employed in the management of multiple myeloma, a bone marrow-based ... Melphalan tablets Advantages Include:. 1. Effective Cancer Management: Melphalan has shown effectiveness in the treatment of ...
Find information on Melphalan (Alkeran, Evomela) in Daviss Drug Guide including dosage, side effects, interactions, nursing ... www.drugguide.com/ddo/view/Davis-Drug-Guide/51473/all/melphalan. Vallerand AHA, Sanoski CAC, Quiring CC. Melphalan. Daviss ... Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Melphalan. In Daviss Drug Guide (18th ed.). F.A. Davis Company. https ... TY - ELEC T1 - melphalan ID - 51473 A1 - Sanoski,Cynthia A, AU - Vallerand,April Hazard, AU - Quiring,Courtney, BT - Daviss ...
Alkeran tablets Melphalan: what exactly is it? Melphalan is a drug that is used to treat cancer, and it works by inhibiting the ... Melphalan oral comes in the form of a tablet that is swallowed. Injectable melphalan is administered by way of intravenous (IV ... While you are on melphalan, you should not breastfeed your child. How is melphalan given? Always make sure to follow all of the ... While Im on melphalan, what should I try to stay away from? Steer clear of ill persons and anyone who could be carrying ...
THIS WEBSITE IS HOSTED BY THE INTERNATIONAL MYELOMA FOUNDATION ("IMF") FOR MULTIPLE MYELOMA SUPPORT GROUPS. THE CONTENT APPEARING ON THIS WEBPAGE IS NOT CONTROLLED OR PROVIDED BY IMF, AND IMF NEITHER WARRANTS NOR GUARANTEES THE ACCURACY OF SUCH CONTENT. THE FOREGOING NOTWITHSTANDING, THE CONTENT IS NOT A SUBSTITUTE FOR ADVICE AND SERVICE PROVIDED BY QUALIFIED AND LICENSED MEDICAL PROFESSIONALS, AND SHOULD NOT BE RELIED ON WITH RESPECT TO ANY HEALTH MATTERS. ANY HEALTH-RELATED INFORMATION FOUND HEREIN IS ONLY MADE AVAILABLE AS PART OF A GENERAL EDUCATIONAL SERVICE.. ...
Animals, Cell Line, DNA, Drug Resistance, Humans, Leukemia L1210, Melphalan, Multiple Myeloma ...
Melphalan Alphalan 2 mg Tablet is treatment of multiple myeloma, a type of blood cancer. the growth and division of cancer ... Be the first to review "Alphalan 2 Mg (Melphalan)" Cancel reply. Your rating *. Rate…. Perfect. Good. Average. Not that bad. ...
Buy high quality Melphalan EP Impurity J from GLP Pharma Standards, the leading manufacturer and supplier of API Impurities, ... Melphalan EP Impurity J; 2-Chloroethoxy Dechloro Melphalan Chemical Name: 4-[[2-(2-Chloroethoxy)ethyl](2-chloroethyl)amino]-L- ... Buy Melphalan EP Impurity J from GLP Pharma Standards at best competitive price. GLP Pharma Standards provides best quality ... Melphalan EP Impurity J. at reasonable price. Get Pharmaceutical Impurities from GLP Pharma Standards. Every compound supplied ...

No FAQ available that match "melphalan"

No images available that match "melphalan"